Case of Hemolytic Disease of the Fetus and Newborn Treated Without Blood Products.

J Pediatr Hematol Oncol

Department of Pediatric, Hematology/Oncology, University of Maryland Children's Hospital, Baltimore, MD.

Published: January 2024

Hemolytic disease of the fetus and newborn (HDFN) affects 3/100,000 to 80/100,000 patients yearly and can cause severe anemia and hyperbilirubinemia. Recombinant human erythropoietin has been used as an adjunct therapy in patients with HDFN and hypo-regenerative anemia in the setting of receiving intrauterine blood transfusions. This case describes a patient with HDFN, in which the family were Jehovah Witnesses, and blood transfusions were declined. The patient had symptomatic anemia with a hematocrit nadir of 18.6%. The patient was successfully treated with recombinant human erythropoietin, ferrous sulfate, and folic acid, avoiding the need for transfusion.

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000002795DOI Listing

Publication Analysis

Top Keywords

hemolytic disease
8
disease fetus
8
fetus newborn
8
recombinant human
8
human erythropoietin
8
blood transfusions
8
case hemolytic
4
newborn treated
4
treated blood
4
blood products
4

Similar Publications

Severe childhood SLE with refractory autoimmune hemolytic anemia-a therapeutic challenge.

BMJ Case Rep

January 2025

Dermatology, Venereology and Leprosy, AIIMS Rishikesh, Rishikesh, Uttarakhand, India

Paediatric Systemic lupus erythematosus (SLE) constitutes 10 to 20% of cases of SLE with more severe disease and higher mortality. We report a case of an adolescent girl with SLE with multisystem involvement who was started on hydroxychloroquine and oral prednisolone. However, due to persistent worsening of skin lesions and falling cell counts, pulsed dexamethasone was initiated which showed improvement in the skin lesions, cell counts, proteinuria and pleural effusion but there was a persistent fall in the haemoglobin.

View Article and Find Full Text PDF

This case report presents a complex medical scenario involving early 60s female patient with a history of chronic lymphocytic leukaemia (CLL) complicated by Evans syndrome, characterised by autoimmune haemolytic anaemia and immune thrombocytopenia. The patient had received various treatments, including steroids, rituximab, cyclosporine and acalabrutinib. The patient's neurological symptoms began around 3 years prior to presentation, with shaking of her right leg, followed by shaking of both hands, particularly the left hand.

View Article and Find Full Text PDF

Background: Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is often refractory and relapsing, leading to increased mortality post-HSCT.

Methods: We retrospectively analyzed the cases of patients with transfusion-dependent β-thalassemia (TDT) who underwent allo-HSCT to study their clinical features, the occurrence of AIHA post-HSCT, and treatment response and to explore the possible pathogenesis of AIHA.

Result: A total of 113 patients were registered in the study, out of whom 14 developed AIHA following allo-HSCT, resulting in a cumulative incidence of 12.

View Article and Find Full Text PDF
Article Synopsis
  • Prenatal exome sequencing (ES) successfully identified both fetal and maternal genetic diagnoses, revealing a shared pathogenic gamma globin variant in a fetus with unexplained anemia and a mother with sickle cell disease (SCD).
  • The identified variant, HbF Mission Bay HBG2, is linked to various blood-related conditions, including cyanosis and hemolytic anemia, which generally emerge in infancy but can persist into adulthood.
  • In this case, the mother's own symptoms from the variant, such as recurrent hypoxia and methemoglobinemia during pregnancy, occurred alongside the fetus's need for multiple blood transfusions and post-birth methemoglobinemia.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!